Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Emergent Biosolutions (EBS)
The company has Return on Asset of (0.048) % which means that on every $100 spent on assets, it lost $0.048. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7467) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.57 in 2024. Return On Capital Employed is likely to gain to -0.14 in 2024. At this time, Emergent Biosolutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 2.4 B in 2024, whereas Deferred Long Term Asset Charges is likely to drop slightly above 9 M in 2024. This firm currently falls under 'Small-Cap' category with a total capitalization of 107.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Emergent Biosolutions's market, we take the total number of its shares issued and multiply it by Emergent Biosolutions's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Based on Macroaxis valuation methodology, the firm appears to be undervalued. Emergent Biosolutions shows a prevailing Real Value of $2.95 per share. The current price of the firm is $1.98. Our model computes the value of Emergent Biosolutions from reviewing the firm fundamentals such as Profit Margin of (0.72) %, current valuation of 869.16 M, and Shares Outstanding of 52.2 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
CEL SCI Corp (CVM)
The company has Return on Asset of (0.5171) % which means that on every $100 spent on assets, it lost $0.5171. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.5825) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to drop to -1. In addition to that, Return On Capital Employed is likely to drop to -1.52. At this time, CEL SCI's Debt To Assets are very stable compared to the past year. The entity currently falls under 'Micro-Cap' category with a total capitalization of 87.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CEL SCI's market, we take the total number of its shares issued and multiply it by CEL SCI's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
8.91 Million
At this time, CEL SCI's Net Debt is very stable compared to the past year.
Cambrex (CBM)
The company has Return on Asset of 8.76 % which means that on every $100 spent on assets, it made $8.76 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 16.0 %, implying that it generated $16.0 on every 100 dollars invested. Cambrex's management efficiency ratios could be used to measure how well Cambrex manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a total capitalization of 2.02 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cambrex's market, we take the total number of its shares issued and multiply it by Cambrex's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Bausch Health Companies (BHC)
The company has Return on Asset of 0.0382 % which means that on every $100 spent on assets, it made $0.0382 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (6.8652) %, meaning that it generated no profit with money invested by stockholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.61, whereas Return On Tangible Assets are projected to grow to (0.06). At present, Bausch Health's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 2.7 B, whereas Total Assets are forecasted to decline to about 14.9 B. This firm currently falls under 'Mid-Cap' category with a total capitalization of 3.17 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bausch Health's market, we take the total number of its shares issued and multiply it by Bausch Health's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
23.51 Billion
At present, Bausch Health's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Asterias Biotherapeutics (AST)
The company has Return on Asset of (0.6763) % which means that on every $100 spent on assets, it lost $0.6763. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (93.1672) %, meaning that it generated no profit with money invested by stockholders. Asterias Biotherapeutics' management efficiency ratios could be used to measure how well Asterias Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Micro-Cap' category with a total capitalization of 52.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Asterias Biotherapeutics's market, we take the total number of its shares issued and multiply it by Asterias Biotherapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Abbott Laboratories (ABT)
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 188.94 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abbott Laboratories's market, we take the total number of its shares issued and multiply it by Abbott Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The entity beta is close to zero. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Flexion Therapeutics will likely underperform. The beta indicator helps investors understand whether Flexion Therapeutics moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Flexion deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The firm currently falls under 'Small-Cap' category with a current market capitalization of 455.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Flexion Therapeutics's market, we take the total number of its shares issued and multiply it by Flexion Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Flex Pharma (FLKS)
The firm beta is close to zero. Flex Pharma returns are very sensitive to returns on the market. As the market goes up or down, Flex Pharma is expected to follow. The beta indicator helps investors understand whether Flex Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Flex deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Nano-Cap' category with a current market capitalization of 444.51 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Flex Pharma's market, we take the total number of its shares issued and multiply it by Flex Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Story appears to be empty
Emergent Biosolutions (EBS)
The company has Return on Asset of (0.048) % which means that on every $100 spent on assets, it lost $0.048. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7467) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.57 in 2024. Return On Capital Employed is likely to gain to -0.14 in 2024. At this time, Emergent Biosolutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 2.4 B in 2024, whereas Deferred Long Term Asset Charges is likely to drop slightly above 9 M in 2024. This firm currently falls under 'Small-Cap' category with a total capitalization of 107.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Emergent Biosolutions's market, we take the total number of its shares issued and multiply it by Emergent Biosolutions's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Based on Macroaxis valuation methodology, the firm appears to be undervalued. Emergent Biosolutions shows a prevailing Real Value of $2.95 per share. The current price of the firm is $1.98. Our model computes the value of Emergent Biosolutions from reviewing the firm fundamentals such as Profit Margin of (0.72) %, current valuation of 869.16 M, and Shares Outstanding of 52.2 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
CEL SCI Corp (CVM)
The company has Return on Asset of (0.5171) % which means that on every $100 spent on assets, it lost $0.5171. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.5825) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to drop to -1. In addition to that, Return On Capital Employed is likely to drop to -1.52. At this time, CEL SCI's Debt To Assets are very stable compared to the past year. The entity currently falls under 'Micro-Cap' category with a total capitalization of 87.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CEL SCI's market, we take the total number of its shares issued and multiply it by CEL SCI's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
8.91 Million
At this time, CEL SCI's Net Debt is very stable compared to the past year.
Cambrex (CBM)
The company has Return on Asset of 8.76 % which means that on every $100 spent on assets, it made $8.76 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 16.0 %, implying that it generated $16.0 on every 100 dollars invested. Cambrex's management efficiency ratios could be used to measure how well Cambrex manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a total capitalization of 2.02 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cambrex's market, we take the total number of its shares issued and multiply it by Cambrex's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Bausch Health Companies (BHC)
The company has Return on Asset of 0.0382 % which means that on every $100 spent on assets, it made $0.0382 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (6.8652) %, meaning that it generated no profit with money invested by stockholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.61, whereas Return On Tangible Assets are projected to grow to (0.06). At present, Bausch Health's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 2.7 B, whereas Total Assets are forecasted to decline to about 14.9 B. This firm currently falls under 'Mid-Cap' category with a total capitalization of 3.17 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bausch Health's market, we take the total number of its shares issued and multiply it by Bausch Health's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
23.51 Billion
At present, Bausch Health's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Asterias Biotherapeutics (AST)
The company has Return on Asset of (0.6763) % which means that on every $100 spent on assets, it lost $0.6763. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (93.1672) %, meaning that it generated no profit with money invested by stockholders. Asterias Biotherapeutics' management efficiency ratios could be used to measure how well Asterias Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Micro-Cap' category with a total capitalization of 52.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Asterias Biotherapeutics's market, we take the total number of its shares issued and multiply it by Asterias Biotherapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Abbott Laboratories (ABT)
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 188.94 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abbott Laboratories's market, we take the total number of its shares issued and multiply it by Abbott Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The entity beta is close to zero. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Flexion Therapeutics will likely underperform. The beta indicator helps investors understand whether Flexion Therapeutics moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Flexion deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The firm currently falls under 'Small-Cap' category with a current market capitalization of 455.47 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Flexion Therapeutics's market, we take the total number of its shares issued and multiply it by Flexion Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Flex Pharma (FLKS)
The firm beta is close to zero. Flex Pharma returns are very sensitive to returns on the market. As the market goes up or down, Flex Pharma is expected to follow. The beta indicator helps investors understand whether Flex Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Flex deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Nano-Cap' category with a current market capitalization of 444.51 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Flex Pharma's market, we take the total number of its shares issued and multiply it by Flex Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Price Exposure Probability Now
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
